Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Large Increase in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 175,300 shares, a growth of 255.6% from the December 15th total of 49,300 shares. Currently, 2.8% of the company’s stock are sold short. Based on an average trading volume of 272,300 shares, the short-interest ratio is presently 0.6 days.

Protagenic Therapeutics Trading Down 0.0 %

Shares of NASDAQ:PTIX traded down $0.00 during trading on Tuesday, hitting $0.47. 183,480 shares of the company were exchanged, compared to its average volume of 185,735. The firm has a fifty day moving average price of $0.58 and a two-hundred day moving average price of $0.64. Protagenic Therapeutics has a fifty-two week low of $0.44 and a fifty-two week high of $1.87. The stock has a market cap of $3.35 million, a price-to-earnings ratio of -0.37 and a beta of 0.28.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.